Report cover image

Technological Advances in Engineered Cell Therapies, Global, 2025–2029

Publisher Frost & Sullivan
Published Sep 02, 2025
SKU # MC20371104

Description

Engineered cell therapies have become a revolutionary medical field, surpassing conventional methods such as systemic medications and prominent immunosuppression to provide long-lasting, programmable, and targeted treatments for complicated diseases. Recent technical developments in engineered cell therapies examine how the rapid growth of cell engineering technologies, including gene editing, synthetic biology, and in vivo programming, has made it possible to develop next-generation cell therapies with formerly unattainable accuracy and versatility. The US FDA's approval of afamitresgene autoleucel (Tecelra) for synovial sarcoma represents a turning point for solid tumor therapies, and T-cell engineering is still at the forefront. Both efficacy and durability are being improved by novel approaches such as integration with checkpoint inhibitors or oncolytic viruses, as well as dual-targeted and armored CAR-T cells. Modular, disease-specific therapeutic responses are further made possible by developments in synthetic biology, such as logic gates, kill switches, and SynNotch receptors. Through closed-loop automation and AI-powered quality control, Cellares, Ori Biotech, and Cellino are addressing manufacturing scalability and consistency. Therapeutic potential in oncology, autoimmune, infectious, and fibrotic diseases is being increased by combining engineered cell therapies with cytokines and small molecules. Notably, initiatives such as Sana Biotechnology's hypoimmune iPSCs for diabetes and Cartesian Therapeutics' RNA-modified cell therapy for myasthenia gravis demonstrate growing momentum beyond oncology. Clinical trial results highlight the predominance of CAR-T platforms in early-stage research, particularly for hematologic malignancies, whereas solid tumors, autoimmune diseases (multiple sclerosis and lupus, for example), and infectious diseases (such as HIV and hepatitis) are gaining popularity. There are significant prospects for increased accessibility and lower costs due to the popularity of off-the-shelf and allogeneic therapies. The future of engineered cell therapies is being shaped by strategic alliances, emerging stakeholders, enabling technologies, and regional growth dynamics, all of which this study examines. The field's therapeutic and commercial impact is expected to significantly increase as it shifts to applications for chronic diseases and scalable platforms and applications.

Table of Contents

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us